title: [Clinical results of recombinant human endostatin combined with chemoradiotherapy for locally advanced nasopharyngeal carcinoma].
abstract: OBJECTIVE
  To compare the short-term efficacy and observe the tolerability and safety of recombinant human endostatin combined with induction chemotherapy followed by chemoradiotherapy for locally advanced nasopharyngeal carcinoma.
  
  
  METHODS
  Fifty-three patients with locally advanced nasopharyngeal carcinoma, who received recombinant human endostatin combined with induction chemotherapy followed by chemoradiotherapy, treated in our department from December 2011 to March 2013 were included in the study group of this study. Another 48 patients, who received induction chemotherapy followed by chemoradiotherapy alone in the same period, were chosen as a control group. The short-term outcome, overall survival (OS), progression-free survival (PFS), and acute side effects of the two groups were compared.
  
  
  RESULTS
  The complete remission rates of nasopharyngeal tumor in the study and control groups were 77.4% and 72.9%, respectively (P=0.154). The complete remission rates of patients with and without cervical lymph node metastasis were 75.5% and 62.6%, respectively, showing a significant difference (P=0.037). The 2-year OS, PFS, and DMFS rates for the study group were 82.3%, 77.2%, and 82.2%, respectively, versus 87.2%, 84.3% and 84.2% for the control group, showing a non-significant differences between the two groups (P=0.938, P=0.551, and P=0.725).
  
  
  CONCLUSIONS
  The short-term results of recombinant human endostatin (Endostar) combined with induction chemotherapy followed by concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma are slightly better than that of induction chemotherapy followed by concurrent chemoradiotherapy alone, with tolerable treatment-related toxicity and no more side effects.
authors.affiliation: Department of Head and Neck Oncology, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China.
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Head and Neck Oncology, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China; Email: jinf8865@yeah.net.
authors.forename: Feng
authors.initials: F
authors.lastname: Jin
authors.affiliation: Department of Head and Neck Oncology, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China.
authors.forename: Weili
authors.initials: W
authors.lastname: Wu
authors.affiliation: Department of Head and Neck Oncology, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China.
authors.forename: Jinhua
authors.initials: J
authors.lastname: Long
authors.affiliation: Department of Head and Neck Oncology, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China.
authors.forename: Xiuyun
authors.initials: X
authors.lastname: Gong
authors.affiliation: Department of Head and Neck Oncology, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China.
authors.forename: Guoyan
authors.initials: G
authors.lastname: Chen
authors.affiliation: Department of Head and Neck Oncology, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China.
authors.forename: Ting
authors.initials: T
authors.lastname: Bi
authors.affiliation: Department of Head and Neck Oncology, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China.
authors.forename: Zhuolin
authors.initials: Z
authors.lastname: Li
authors.affiliation: Department of Head and Neck Oncology, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China.
authors.forename: Qianyong
authors.initials: Q
authors.lastname: He
authors.affiliation: Department of Head and Neck Oncology, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China.
authors.forename: Faqiang
authors.initials: F
authors.lastname: Ma
authors.affiliation: Department of Head and Neck Oncology, Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China.
authors.forename: Rui
authors.initials: R
authors.lastname: Wang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma; D059248:Chemoradiotherapy; D002945:Cisplatin; D018572:Disease-Free Survival; D043169:Endostatins / Q000627:therapeutic use; D006801:Humans; D060828:Induction Chemotherapy; D008207:Lymphatic Metastasis; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D012074:Remission Induction
chemical_list: D043169:Endostatins; D002945:Cisplatin